FGF-21 Elevated IL-10 Production to Correct LPS-Induced Inflammation

Area of Science:

• Immunology
• Endocrinology
• Molecular Biology

Background:

• Fibroblast growth factor 21 (FGF-21) is recognized as a key metabolic regulator.
• Emerging evidence suggests FGF-21 may also play a role in immune system modulation.
• Understanding FGF-21's non-metabolic functions is crucial for novel therapeutic development.

Purpose of the Study:

• To investigate the potential anti-inflammatory and immunoregulatory roles of FGF-21.
• To elucidate the molecular mechanisms underlying FGF-21's effects on inflammation.
• To assess FGF-21 as a therapeutic target for inflammatory conditions.

Main Methods:

• In vivo studies using LPS-induced inflammation models.
• In vitro experiments with THP-1 cells to assess cytokine expression.
• Analysis of signaling pathways, including NF-κB and ERK1/2.

Main Results:

• Exogenous FGF-21 treatment significantly reduced LPS-induced inflammation in vivo.
• FGF-21 inhibited the expression of Interleukin-1 beta (IL-1β) in THP-1 cells stimulated with LPS.
• FGF-21's mechanism involves the elevation of Interleukin-10 (IL-10) via the ERK1/2 pathway, independent of the NF-κB pathway.

Conclusions:

• FGF-21 demonstrates significant anti-inflammatory and immunomodulatory properties.
• The study highlights FGF-21's potential as a therapeutic agent for inflammatory disorders.
• Targeting FGF-21 offers a promising strategy for managing inflammatory diseases.